We are pleased to release the news that on 30 December 2022, that we have through Rxilient Medical Pte. Ltd. acquired a potential blockbuster innovative product in dermatology filed from CMS Aesthetics by entering into a sublicense and collaboration agreement obtaining the license for the development, production, registration and commercialization of Ruxolitinib cream in Taiwan and eleven countries in Southeast Asia (“Territory”), commencing on its effective date.
